CN101501009A - Cgrp受体拮抗剂 - Google Patents
Cgrp受体拮抗剂 Download PDFInfo
- Publication number
- CN101501009A CN101501009A CNA2007800297374A CN200780029737A CN101501009A CN 101501009 A CN101501009 A CN 101501009A CN A2007800297374 A CNA2007800297374 A CN A2007800297374A CN 200780029737 A CN200780029737 A CN 200780029737A CN 101501009 A CN101501009 A CN 101501009A
- Authority
- CN
- China
- Prior art keywords
- base
- alkyl
- group
- described compound
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Addiction (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81317806P | 2006-06-13 | 2006-06-13 | |
US60/813,178 | 2006-06-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101501009A true CN101501009A (zh) | 2009-08-05 |
Family
ID=38832524
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2007800297374A Pending CN101501009A (zh) | 2006-06-13 | 2007-06-13 | Cgrp受体拮抗剂 |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP2027106A2 (es) |
JP (1) | JP5382799B2 (es) |
CN (1) | CN101501009A (es) |
AR (1) | AR061362A1 (es) |
AU (1) | AU2007258294A1 (es) |
CA (1) | CA2655085A1 (es) |
IL (1) | IL195807A0 (es) |
MX (1) | MX2008015906A (es) |
NZ (1) | NZ574097A (es) |
TW (1) | TW200813019A (es) |
WO (1) | WO2007146349A2 (es) |
ZA (1) | ZA200810791B (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107207567A (zh) * | 2015-01-06 | 2017-09-26 | 辉凌公司 | Cgrp拮抗剂肽 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7834000B2 (en) * | 2006-06-13 | 2010-11-16 | Vertex Pharmaceuticals Incorporated | CGRP receptor antagonists |
US8383629B2 (en) * | 2008-02-27 | 2013-02-26 | Vitae Pharmaceuticals, Inc. | Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 |
JP5923375B2 (ja) * | 2012-04-24 | 2016-05-24 | 花王株式会社 | Cgrp応答性促進剤 |
US8906951B1 (en) | 2013-06-24 | 2014-12-09 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
US9198898B2 (en) | 2013-06-24 | 2015-12-01 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
WO2019112024A1 (ja) * | 2017-12-08 | 2019-06-13 | キッセイ薬品工業株式会社 | ピロリジン化合物 |
WO2019141808A1 (en) | 2018-01-19 | 2019-07-25 | Idorsia Pharmaceuticals Ltd | C5a receptor modulators |
US20210121541A1 (en) * | 2019-07-05 | 2021-04-29 | Allergan Pharmaceuticals International Limited | CGRP Antagonists and Clostridial Derivatives for the Treatment of Neuropsychiatric and Neurological Disorders |
WO2021005493A1 (en) * | 2019-07-05 | 2021-01-14 | Allergan Pharmaceuticals International Limited | Cgrp antagonists and botulinum toxins for the treatment of inflammatory and neurologic disorders |
US11976067B2 (en) | 2022-01-18 | 2024-05-07 | Maze Therapeutics, Inc. | APOL1 inhibitors and methods of use |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2487976C (en) * | 2002-06-05 | 2011-07-26 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
GB2396613A (en) * | 2002-08-23 | 2004-06-30 | Ionix Pharmaceuticals Ltd | Five-membered heterocyclic compounds in the treatment of chronic and acute pain |
JO2355B1 (en) * | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
JP4705912B2 (ja) * | 2003-06-26 | 2011-06-22 | メルク・シャープ・エンド・ドーム・コーポレイション | ベンゾジアゼピンcgrp受容体拮抗物質 |
-
2007
- 2007-06-13 WO PCT/US2007/013896 patent/WO2007146349A2/en active Application Filing
- 2007-06-13 NZ NZ574097A patent/NZ574097A/en not_active IP Right Cessation
- 2007-06-13 ZA ZA200810791A patent/ZA200810791B/xx unknown
- 2007-06-13 EP EP07796082A patent/EP2027106A2/en not_active Withdrawn
- 2007-06-13 AR ARP070102587A patent/AR061362A1/es unknown
- 2007-06-13 JP JP2009515476A patent/JP5382799B2/ja not_active Expired - Fee Related
- 2007-06-13 CN CNA2007800297374A patent/CN101501009A/zh active Pending
- 2007-06-13 TW TW096121362A patent/TW200813019A/zh unknown
- 2007-06-13 CA CA002655085A patent/CA2655085A1/en not_active Abandoned
- 2007-06-13 MX MX2008015906A patent/MX2008015906A/es active IP Right Grant
- 2007-06-13 AU AU2007258294A patent/AU2007258294A1/en not_active Abandoned
-
2008
- 2008-12-09 IL IL195807A patent/IL195807A0/en unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107207567A (zh) * | 2015-01-06 | 2017-09-26 | 辉凌公司 | Cgrp拮抗剂肽 |
CN107207567B (zh) * | 2015-01-06 | 2021-11-23 | 辉凌公司 | Cgrp拮抗剂肽 |
Also Published As
Publication number | Publication date |
---|---|
AU2007258294A1 (en) | 2007-12-21 |
MX2008015906A (es) | 2009-03-06 |
IL195807A0 (en) | 2009-09-01 |
CA2655085A1 (en) | 2007-12-21 |
JP5382799B2 (ja) | 2014-01-08 |
JP2009539997A (ja) | 2009-11-19 |
TW200813019A (en) | 2008-03-16 |
NZ574097A (en) | 2012-01-12 |
AR061362A1 (es) | 2008-08-20 |
WO2007146349A3 (en) | 2008-09-25 |
EP2027106A2 (en) | 2009-02-25 |
ZA200810791B (en) | 2010-03-31 |
WO2007146349A2 (en) | 2007-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101501009A (zh) | Cgrp受体拮抗剂 | |
CN101076527B (zh) | 三环酰苯胺螺乙内酰脲cgrp受体拮抗剂 | |
CN101014602B (zh) | 单环酰苯胺螺环内酰胺cgrp受体拮抗剂 | |
CN101516875A (zh) | Cgrp受体拮抗剂 | |
AU2010317501B2 (en) | N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors | |
CN1812982B (zh) | 苯并二氮杂*cgrp受体拮抗剂 | |
CN101014576B (zh) | 芳基螺内酰胺cgrp受体拮抗剂 | |
US7834000B2 (en) | CGRP receptor antagonists | |
JP4673294B2 (ja) | 二環式アニリドスピロヒダントインcgrp受容体拮抗物質 | |
CN100418948C (zh) | 羟基吡啶cgrp受体抗拮抗剂 | |
CN103328478B (zh) | 哌啶酮羧酰胺氮杂茚满cgrp受体拮抗剂 | |
CN101018781A (zh) | 双环n-酰苯胺螺内酰胺cgrp受体拮抗剂 | |
CN101232887A (zh) | 杂环苯并二氮杂䓬cgrp受体拮抗剂 | |
AU2011268073B2 (en) | D2 antagonists, methods of synthesis and methods of use | |
CN101448821A (zh) | 羧酰胺螺内酰胺降钙素基因相关肽受体拮抗剂 | |
CN101443323A (zh) | 取代的螺环cgrp受体拮抗剂 | |
CN101208303A (zh) | Cgrp受体拮抗剂 | |
CN101014345A (zh) | 三环酰苯胺螺环内酰胺cgrp受体拮抗剂 | |
KR20110053266A (ko) | 아미노트리아졸로피리딘 및 이것의 키나제 억제제로서의 용도 | |
CA2778316A1 (en) | N-2 pyrazolospiroketone acetyl-coa carboxylase inhibitors | |
US8163737B2 (en) | CGRP receptor antagonists | |
JP2011511792A (ja) | Cgrp受容体アンタゴニストのプロドラッグ | |
NZ613181B2 (en) | Heterocyclic compounds for the inhibition of pask | |
NZ613181A (en) | Heterocyclic compounds for the inhibition of pask |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1135384 Country of ref document: HK |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20090805 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1135384 Country of ref document: HK |